
|Articles|February 26, 2007
Helixate FS, Mix2Vial now packaged together
Advertisement
CSL Behring has begun packaging Helixate FS, its advanced recombinant FVIII (rFVIII) factor product for the treatment of hemophilia A, with Mix2Vial, its needle-free transfer device. The new packaging was developed in response to comprehensive market research of customers and to meet the latest OSHA requirements. For more information, visit
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
IRA Drug Price Negotiations Threatening Pharmacies’ Financial Sustainability
2
Congressional Spending Bill to Include Key PBM Contracting Reform
3
OTC Medications for Cold and Flu Remain Cornerstone of Community Care
4
More Than 200 Organizations Denounce Childhood Vaccine Schedule Change
5
















